Patent application number | Description | Published |
20080260728 | Treatment of Severe Multiple Sclerosis - Methods of treating multiple sclerosis are disclosed. | 10-23-2008 |
20090010926 | Extended Treatment of Multiple Sclerosis - Methods for extended treatment of multiple sclerosis are described. | 01-08-2009 |
20090169477 | DELAYING OR PREVENTING ONSET OF MULTIPLE SCLEROSIS - Methods of treating persons at risk for relapsing MS are described. | 07-02-2009 |
20090176256 | Methods and Products for Evaluating an Immune Response to a Therapeutic Protein - The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre. | 07-09-2009 |
20090202527 | TREATMENT FOR MULTIPLE SCLEROSIS - Methods of treating multiple sclerosis and other disorders are disclosed. | 08-13-2009 |
20120195884 | METHODS AND PRODUCTS FOR EVALUATING AN IMMUNE RESPONSE TO A THERAPEUTIC PROTEIN - The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre. | 08-02-2012 |
20120276048 | EXTENDED TREATMENT OF MULTIPLE SCLEROSIS - Methods for extended treatment of multiple sclerosis are described. | 11-01-2012 |
20150030590 | TREATMENT OF SEVERE MULTIPLE SCLEROSIS - Methods of treating multiple sclerosis are disclosed. | 01-29-2015 |
20150071917 | METHODS AND PRODUCTS FOR EVALUATING AN IMMUNE RESPONSE TO A THERAPEUTIC PROTEIN - The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre. | 03-12-2015 |